Roche reports encouraging results from mid-stage study of cancer drug atezolizumab

11 January 2016
roche-big

Swiss drug major Roche (ROG: SIX) has reported encouraging results from a study of its closely monitored cancer immunotherapy, atezolizumab.

The company said a mid-stage trial of atezolizumab in people with locally advanced or metastatic urothelial carcinoma (mUC), showed median overall survival of 11.4 months in people with higher levels of PD-L1 expression and 7.9 months in the overall study population.

The world's biggest maker of cancer drugs said the study showed that 84% of people who responded to atezolizumab continued to respond regardless of their PD-L1 status when the results were assessed with longer median follow-up of 11.7 months.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical